|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Roder DM: The epidemiology of gastric
cancer. Gastric Cancer. 5(Suppl 1): 5–11. 2002. View Article : Google Scholar
|
|
3
|
Gallo A and Cha C: Updates on esophageal
and gastric cancers. World J Gastroenterol. 12:3237–3242. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gunderson LL: Gastric cancer - patterns of
relapse after surgical resection. Semin Radiat Oncol. 12:150–161.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al MAGIC Trial Participants: Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bang YJ, Kim YW, Yang HK, Chung HC, Park
YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al CLASSIC trial
investigators: Adjuvant capecitabine and oxaliplatin for gastric
cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label,
randomised controlled trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mesner PW Jr, Budihardjo II and Kaufmann
SH: Chemotherapy-induced apoptosis. Adv Pharmacol. 41:461–499.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaufmann SH and Earnshaw WC: Induction of
apoptosis by cancer chemotherapy. Exp Cell Res. 256:42–49. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hannun YA: Apoptosis and the dilemma of
cancer chemotherapy. Blood. 89:1845–1853. 1997.PubMed/NCBI
|
|
10
|
Kostova I: Platinum complexes as
anticancer agents. Recent Patents Anticancer Drug Discov. 1:1–22.
2006. View Article : Google Scholar
|
|
11
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakagawa Y, Sedukhina AS, Okamoto N,
Nagasawa S, Suzuki N, Ohta T, Hattori H, Roche-Molina M, Narváez
AJ, Jeyasekharan AD, et al: NF-κB signaling mediates acquired
resistance after PARP inhibition. Oncotarget. 6:3825–3839. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Halilovic E, She QB, Ye Q, Pagliarini R,
Sellers WR, Solit DB and Rosen N: PIK3CA mutation uncouples tumor
growth and cyclin D1 regulation from MEK/ERK and mutant KRAS
signaling. Cancer Res. 70:6804–6814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Michaelis M, Rothweiler F, Barth S, Cinatl
J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling
A, Rödel F, et al: Adaptation of cancer cells from different
entities to the MDM2 inhibitor nutlin-3 results in the emergence of
p53-mutated multi-drug-resistant cancer cells. Cell Death Dis.
2:e2432011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin X, Zhang X, Wang Q, Li J, Zhang P,
Zhao M and Li X: Perifosine downregulates MDR1 gene expression and
reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB
signaling pathway in a human breast cancer cell line. Neoplasma.
59:248–256. 2012. View Article : Google Scholar
|
|
17
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma L, Reinhardt F, Pan E, Soutschek J,
Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA:
Therapeutic silencing of miR-10b inhibits metastasis in a mouse
mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar
|
|
22
|
Cho WC: MicroRNAs in cancer - from
research to therapy. Biochim Biophys Acta. 1805:209–217. 2010.
|
|
23
|
Gabriely G, Teplyuk NM and Krichevsky AM:
Context effect: microRNA-10b in cancer cell proliferation, spread
and death. Autophagy. 7:1384–1386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu
G, Zhao R, Huang H, Wang X, Qiao Y, et al: MiR-152 and miR-185
co-contribute to ovarian cancer cells cisplatin sensitivity by
targeting DNMT1 directly: A novel epigenetic therapy independent of
decitabine. Oncogene. 33:378–386. 2014. View Article : Google Scholar
|
|
25
|
Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li
K, Zhou L, Sun Y, Li M, Zhou J, et al: miR-508-5p regulates
multidrug resistance of gastric cancer by targeting ABCB1 and
ZNRD1. Oncogene. 33:3267–3276. 2014. View Article : Google Scholar
|
|
26
|
Sui C, Meng F, Li Y and Jiang Y: miR-148b
reverses cisplatin-resistance in non-small cell cancer cells via
negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1)
expression. J Transl Med. 13:1322015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT
and Zhang CP: MicroRNAs contribute to the chemoresistance of
cisplatin in tongue squamous cell carcinoma lines. Oral Oncol.
46:317–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei B, Huang QY, Huang SR, Mai W and Zhong
XG: MicroRNA-34a attenuates the proliferation, invasion and
metastasis of gastric cancer cells via downregulation of MET. Mol
Med Rep. 12:5255–5261. 2015.PubMed/NCBI
|
|
31
|
Du Y, Zhu M, Zhou X, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W, et al: miR-20a enhances cisplatin
resistance of human gastric cancer cell line by targeting NFKBIB.
Tumour Biol. 37:1261–1269. 2016. View Article : Google Scholar
|
|
32
|
Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni
L, Zhang WG, Nan KJ, Song TS and Huang C: MicroRNA profiling of
human gastric cancer. Mol Med Rep. 2:963–970. 2009.PubMed/NCBI
|
|
33
|
Wong MY, Yu Y, Walsh WR and Yang JL:
microRNA-34 family and treatment of cancers with mutant or
wild-type p53 (Review). Int J Oncol. 38:1189–1195. 2011.PubMed/NCBI
|
|
34
|
Kumar B, Yadav A, Lang J, Teknos TN and
Kumar P: Dysregulation of microRNA-34a expression in head and neck
squamous cell carcinoma promotes tumor growth and tumor
angiogenesis. PLoS One. 7:e376012012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen Z, Zhan G, Ye D, Ren Y, Cheng L, Wu Z
and Guo J: MicroRNA-34a affects the occurrence of laryngeal
squamous cell carcinoma by targeting the antiapoptotic gene
survivin. Med Oncol. 29:2473–2480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, Guessous F, Zhang Y, Dipierro C,
Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen
TD, et al: MicroRNA-34a inhibits glioblastoma growth by targeting
multiple oncogenes. Cancer Res. 69:7569–7576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cho WC: OncomiRs: The discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lutterbach B, Zeng Q, Davis LJ, Hatch H,
Hang G, Kohl NE, Gibbs JB and Pan BS: Lung cancer cell lines
harboring MET gene amplification are dependent on Met for growth
and survival. Cancer Res. 67:2081–2088. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takeuchi H, Bilchik A, Saha S, Turner R,
Wiese D, Tanaka M, Kuo C, Wang HJ and Hoon DS: c-MET expression
level in primary colon cancer: A predictor of tumor invasion and
lymph node metastases. Clin Cancer Res. 9:1480–1488.
2003.PubMed/NCBI
|
|
40
|
Sawada K, Radjabi AR, Shinomiya N, Kistner
E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande
Woude GF, et al: c-Met overexpression is a prognostic factor in
ovarian cancer and an effective target for inhibition of peritoneal
dissemination and invasion. Cancer Res. 67:1670–1679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dang Y, Luo D, Rong M and Chen G:
Underexpression of miR-34a in hepatocellular carcinoma and its
contribution towards enhancement of proliferating inhibitory
effects of agents targeting c-MET. PLoS One. 8:e610542013.
View Article : Google Scholar : PubMed/NCBI
|
